The United Kingdom has opened up another front of its 100,000 Genomes Project. Having started off sequencing the genomes of people with rare diseases, the team behind the initiative are now ready to take aim at their other big target: cancer.
The American Society of Clinical Oncology unveiled its framework for assessing cancer drugs earlier this summer, breaking new ground in helping doctors size up competing treatments. Now, the National Comprehensive Cancer Network is going a few steps farther.
A pair of VC darlings have hooked up to speed the development of targeted cancer therapies. The deal sees Flatiron Health combine its oncology cloud system with blood test data from Guardant Health to give drug developers a platform on which they can identify molecular targets and support enrollment in clinical trials.
Cancer doctors at the famed Mayo Clinic have been up in arms about escalating prices of cancer drugs. Now they have recruited a bunch of colleagues and are trying to rile up the public in hopes of starting a patient-based grassroots movement.
The maker of the first MRI-guided radiation cancer therapy system, ViewRay, has raised more cash since it cancelled a planned $52 million IPO in April than it expected to raise in that offering. It's raised a total of $76.7 million--$26.7 million of that in connection with a reverse merger that it just completed on July 23 and another $50 million in debt from royalty investor CRG in late June.
Perimeter Medical Imaging isn't alone in its aspirations to offer surgeons a better tool to visualize surgical tissue perimeters--but it is one of the newer entrants to the race. The startup has raised a $5 million Series A financing that it expects will be sufficient to complete an ongoing clinical trial, as well as to secure regulatory clearance for its first tissue imaging product.
European researchers from several companies and academic centers are working toward creating a photonic laser-based device that would enable the diagnosis and monitoring of cancer patients in the physician's office. The four-year project is funded via Horizon 2020, the largest and latest EU R&D initiative that's investing a total of almost €80 billion ($86.9 billion) from 2014 to 2020 to stimulate technology transfer.
ViewRay has nabbed up to $50 million in debt financing from healthcare investor CRG after canceling a proposed $52 million IPO in April. The cash will go to help commercialize its MRI-guided radiation therapy as well as to refinance existing debt.
In 2012, the Morris Animal Foundation launched its Golden Retriever Lifetime Study, which is expected to last 15 years and is aimed at identifying important risk factors for cancer and other diseases. Now the foundation has released its first paper from the study, which was published in a special cancer-themed issue of the journal Philosophical Transactions B.
Women generally fare better than men after picking up cancer, but research presented at the Cancer Outcomes Conference in Belfast, Northern Ireland, found that the reverse is true among sufferers of bladder cancer. The information has informed a U.K. public advertising campaign to raise awareness of the disease.